• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国南方膀胱尿路上皮癌患者的深度基因组测序:一项单中心研究

Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study.

作者信息

Li Dong-Yang, Yang Fei, Liao Wei-Qiang, Zhou Xiang-Fu, Li Wen-Biao, Cai Jia-Rong, Liu Bo-Long, Luo Yun, Zhan Hai-Lun

机构信息

Department of Urology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Department of Urology, Luoding People's Hospital, Luoding, China.

出版信息

Front Oncol. 2021 May 14;11:538927. doi: 10.3389/fonc.2021.538927. eCollection 2021.

DOI:10.3389/fonc.2021.538927
PMID:34055593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8160294/
Abstract

OBJECTIVE

Bladder urothelial carcinoma (BUC) is a common urological malignancy with molecular heterogeneity. However, the genetic feature of Chinese BUC patients is still not well-identified.

METHODS

We performed deep sequencing by a large panel (450 genes) on 22 BUC samples and using matched normal bladder tissue as control. Genomic alterations (GAs), pathways and Tumor Mutation Burden (TMB) were investigated.

RESULTS

The frequencies of GAs (, 54.5%; , 27.3%; , 22.7%; , 18.2%; , 18.2% and , 18.2%) were significantly higher in Chinese than Western BUC patients. Other GAs' frequencies were in accordance with previous study (, 50.0%; , 31.8%; , 22.7%; etc.). Besides, we detected gene amplification in , etc. The gene fusion/rearrangement took place in the chromosome 11, 12, 14, 17, 19, 22, and Y. Other than cell cycle and PI3K-AKT-mTOR, mutated genes were more associated with the transcription factor, chromatin modification signaling pathways. Interestingly, the TMB value was significantly higher in the BUC patients at stages T1-T2 than T3-T4 ( = 0.025).

CONCLUSION

Deep genomic sequencing of BUC can provide new clues on the unique GAs of Chinese patients and assist in therapeutic decision.

摘要

目的

膀胱尿路上皮癌(BUC)是一种具有分子异质性的常见泌尿系统恶性肿瘤。然而,中国BUC患者的基因特征仍未得到充分明确。

方法

我们对22例BUC样本进行了大panel(450个基因)深度测序,并以匹配的正常膀胱组织作为对照。研究了基因组改变(GAs)、信号通路和肿瘤突变负荷(TMB)。

结果

中国BUC患者的GAs频率(,54.5%;,27.3%;,22.7%;,18.2%;,18.2%和,18.2%)显著高于西方BUC患者。其他GAs频率与先前研究一致(,50.0%;,31.8%;,22.7%等)。此外,我们检测到了等基因的扩增。基因融合/重排在11、12、14、17、19、22和Y染色体上发生。除细胞周期和PI3K-AKT-mTOR外,突变基因与转录因子、染色质修饰信号通路的相关性更强。有趣的是,T1-T2期BUC患者的TMB值显著高于T3-T4期(=0.025)。

结论

BUC的深度基因组测序可为中国患者独特的GAs提供新线索,并有助于治疗决策。

相似文献

1
Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study.中国南方膀胱尿路上皮癌患者的深度基因组测序:一项单中心研究
Front Oncol. 2021 May 14;11:538927. doi: 10.3389/fonc.2021.538927. eCollection 2021.
2
Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.通过靶向下一代测序鉴定中国人群尿路上皮膀胱癌的潜在治疗靶点。
Cancer Biol Ther. 2020 Aug 2;21(8):709-716. doi: 10.1080/15384047.2020.1763148. Epub 2020 May 23.
3
TGFBR3 co-downregulated with GATA3 is associated with methylation of the GATA3 gene in bladder urothelial carcinoma.TGFBR3 与 GATA3 共下调与膀胱癌尿路上皮癌中 GATA3 基因的甲基化有关。
Anat Rec (Hoboken). 2013 Nov;296(11):1717-23. doi: 10.1002/ar.22802. Epub 2013 Oct 4.
4
Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.膀胱和上尿路移行细胞癌的遗传差异:对治疗的影响。
Eur Urol Oncol. 2021 Apr;4(2):170-179. doi: 10.1016/j.euo.2020.12.007. Epub 2020 Dec 30.
5
Elevated preoperative plasma fibrinogen level is an independent predictor of malignancy and advanced stage disease in patients with bladder urothelial tumors.术前血浆纤维蛋白原水平升高是膀胱尿路上皮肿瘤患者恶性肿瘤和晚期疾病的独立预测因子。
Int J Surg. 2016 Dec;36(Pt A):249-254. doi: 10.1016/j.ijsu.2016.11.010. Epub 2016 Nov 5.
6
α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients.α4 通过调节 E-钙黏蛋白促进膀胱尿路上皮癌细胞侵袭和/或转移,是膀胱尿路上皮癌患者预后的预测因子。
Eur J Cancer. 2014 Mar;50(4):840-51. doi: 10.1016/j.ejca.2013.11.038. Epub 2014 Jan 2.
7
Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma.影响膀胱尿路上皮癌预后的关键通路和基因的鉴定
Onco Targets Ther. 2017 Mar 20;10:1673-1686. doi: 10.2147/OTT.S131386. eCollection 2017.
8
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.RB1 和 TP53 共突变与膀胱癌对免疫检查点抑制剂反应的基因组生物标志物密切相关。
BMC Cancer. 2021 Apr 20;21(1):432. doi: 10.1186/s12885-021-08078-y.
9
Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.通过全外显子测序对中国人群非肌层浸润性和肌层浸润性膀胱癌中差异突变基因的比较分析
Front Genet. 2022 Mar 25;13:831146. doi: 10.3389/fgene.2022.831146. eCollection 2022.
10
SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.SPAG5 通过激活 AKT/mTOR 通路上调 Wnt3 促进膀胱尿路上皮癌增殖并抑制细胞凋亡,且其表达水平与患者预后不良相关。
Oncogene. 2018 Jul;37(29):3937-3952. doi: 10.1038/s41388-018-0223-2. Epub 2018 Apr 17.

引用本文的文献

1
Single-cell sequencing technologies in bladder cancer research: Applications and challenges.膀胱癌研究中的单细胞测序技术:应用与挑战
Front Genet. 2022 Oct 19;13:1027909. doi: 10.3389/fgene.2022.1027909. eCollection 2022.

本文引用的文献

1
CNSA: a data repository for archiving omics data.中国科学院生物多样性委员会:一个用于存储组学数据的数据库。
Database (Oxford). 2020 Jan 1;2020. doi: 10.1093/database/baaa055.
2
Comprehensive fundamental somatic variant calling and quality management strategies for human cancer genomes.全面的人类癌症基因组体细胞变异calling 和质量管理策略。
Brief Bioinform. 2021 May 20;22(3). doi: 10.1093/bib/bbaa083.
3
Significance of TP53 mutation in bladder cancer disease progression and drug selection.TP53突变在膀胱癌疾病进展和药物选择中的意义。
PeerJ. 2019 Dec 16;7:e8261. doi: 10.7717/peerj.8261. eCollection 2019.
4
Identification of an immunotherapy-responsive molecular subtype of bladder cancer.鉴定膀胱癌免疫治疗反应的分子亚型。
EBioMedicine. 2019 Dec;50:238-245. doi: 10.1016/j.ebiom.2019.10.058. Epub 2019 Nov 15.
5
Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.多组学分析肿瘤突变负担与膀胱癌免疫浸润的关系。
J Cell Physiol. 2020 Apr;235(4):3849-3863. doi: 10.1002/jcp.29279. Epub 2019 Oct 9.
6
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma.HBV 相关肝细胞癌的综合蛋白质基因组特征分析。
Cell. 2019 Oct 3;179(2):561-577.e22. doi: 10.1016/j.cell.2019.08.052.
7
An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.一种用于癌症靶向和免疫治疗的准确而全面的临床测序检测方法。
Oncologist. 2019 Dec;24(12):e1294-e1302. doi: 10.1634/theoncologist.2019-0236. Epub 2019 Aug 13.
8
Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.通过靶向下一代测序鉴定出切除复发性未分化多形性肉瘤中的致病性和可靶向遗传改变。
Cancer Genomics Proteomics. 2019 May-Jun;16(3):221-228. doi: 10.21873/cgp.20127.
9
Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer.全基因组测序鉴定出 ADGRG6 增强子突变和 FRS2 重复作为膀胱癌中与血管生成相关的驱动因素。
Nat Commun. 2019 Feb 12;10(1):720. doi: 10.1038/s41467-019-08576-5.
10
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.